GSK Statistics
Total Valuation
GSK has a market cap or net worth of $101.44 billion. The enterprise value is $120.27 billion.
Important Dates
The next estimated earnings date is Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Nov 14, 2025 |
Share Statistics
GSK has 4.03 billion shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.03B |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 86.60% |
| Float | 3.87B |
Valuation Ratios
The trailing PE ratio is 13.74 and the forward PE ratio is 10.42.
| PE Ratio | 13.74 |
| Forward PE | 10.42 |
| PS Ratio | 2.35 |
| Forward PS | 2.94 |
| PB Ratio | 4.79 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.69 |
| P/OCF Ratio | 9.68 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.40, with an EV/FCF ratio of 13.86.
| EV / Earnings | 16.29 |
| EV / Sales | 2.78 |
| EV / EBITDA | 9.40 |
| EV / EBIT | 13.14 |
| EV / FCF | 13.86 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 1.13.
| Current Ratio | 0.84 |
| Quick Ratio | 0.54 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 1.82 |
| Debt / FCF | 2.75 |
| Interest Coverage | 10.96 |
Financial Efficiency
Return on equity (ROE) is 41.52% and return on invested capital (ROIC) is 13.51%.
| Return on Equity (ROE) | 41.52% |
| Return on Assets (ROA) | 7.13% |
| Return on Invested Capital (ROIC) | 13.51% |
| Return on Capital Employed (ROCE) | 17.02% |
| Revenue Per Employee | $630,016 |
| Profits Per Employee | $107,608 |
| Employee Count | 68,629 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.47 |
Taxes
In the past 12 months, GSK has paid $1.28 billion in taxes.
| Income Tax | 1.28B |
| Effective Tax Rate | 13.56% |
Stock Price Statistics
The stock price has increased by +49.30% in the last 52 weeks. The beta is 0.25, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +49.30% |
| 50-Day Moving Average | 48.15 |
| 200-Day Moving Average | 41.54 |
| Relative Strength Index (RSI) | 63.21 |
| Average Volume (20 Days) | 3,388,080 |
Short Selling Information
The latest short interest is 11.23 million, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 11.23M |
| Short Previous Month | 12.55M |
| Short % of Shares Out | 0.56% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.67 |
Income Statement
In the last 12 months, GSK had revenue of $43.24 billion and earned $7.39 billion in profits. Earnings per share was $1.79.
| Revenue | 43.24B |
| Gross Profit | 31.32B |
| Operating Income | 9.15B |
| Pretax Income | 9.43B |
| Net Income | 7.39B |
| EBITDA | 12.80B |
| EBIT | 9.15B |
| Earnings Per Share (EPS) | $1.79 |
Full Income StatementBalance Sheet
The company has $4.44 billion in cash and $23.86 billion in debt, with a net cash position of -$19.42 billion or -$4.82 per share.
| Cash & Cash Equivalents | 4.44B |
| Total Debt | 23.86B |
| Net Cash | -19.42B |
| Net Cash Per Share | -$4.82 |
| Equity (Book Value) | 21.17B |
| Book Value Per Share | 5.39 |
| Working Capital | -4.69B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.47 billion and capital expenditures -$1.77 billion, giving a free cash flow of $8.68 billion.
| Operating Cash Flow | 10.47B |
| Capital Expenditures | -1.77B |
| Free Cash Flow | 8.68B |
| FCF Per Share | $2.16 |
Full Cash Flow StatementMargins
Gross margin is 72.43%, with operating and profit margins of 21.17% and 17.08%.
| Gross Margin | 72.43% |
| Operating Margin | 21.17% |
| Pretax Margin | 21.81% |
| Profit Margin | 17.08% |
| EBITDA Margin | 29.59% |
| EBIT Margin | 21.17% |
| FCF Margin | 20.07% |
Dividends & Yields
This stock pays an annual dividend of $1.68, which amounts to a dividend yield of 3.33%.
| Dividend Per Share | $1.68 |
| Dividend Yield | 3.33% |
| Dividend Growth (YoY) | 9.58% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 93.81% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 3.25% |
| Earnings Yield | 7.28% |
| FCF Yield | 8.56% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 3.59% |
| EPS Growth Forecast (5Y) | 23.71% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 1.81 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.81 |
| Piotroski F-Score | 7 |
